The key to living longer could be linked to a surprising substance, suggests a study

A new study suggests that psilocybin, also known as magical fungi, could extend useful life.

Researchers at the Department of Medicine at the University of Emory in Atlanta, Georgia, discovered that psilocybin extended cellular life and improved survival in aged mice.

Psilocybin is the “natural psychedelic compound produced by hallucinogenic fungi”, as defined in the study.

The unique dose of ‘Magic Mushrooms’ provides 5 years of relief of depression, researchers find

Psilocybin has recently received attention due to “considerable clinical evidence” due to its potential in the treatment of various psychiatric and neurodegenerative conditions, the researchers said.

The study, published in Nature magazine, discovered the first experimental evidence that psilocin treatment, “active metabolite” in psilocybin, increases longevity in aged mice.

This suggests that psilocybin can be a “powerful geroprotective agent,” the researchers wrote.

The co -author Louise Hecker of the University of Emory said the data suggests that psilocybin impacts “multiple characteristics of aging.”

This includes reducing oxidative stress levels and preventing DNA damage, also known as preserving the “length of telomeres.” (Telomeres are DNA-protein structures at the ends of chromosomes, which help prevent cell damage).

Parkinson’s patients take ‘magical fungi’ see the key benefits, the study finds

“Psilocibin seems to slow the ‘wear’ that accompanies aging,” said Hecker in an interview with News Digital. “Mice and cells are healthier and live significantly more.”

The treatment led to “a dramatic impact on the extensions of cell life” and increased the survival of the mice, even when it was administered later in life, the researcher said.

The mice also seemed healthier, growing black hair that once was white.

“Most of what we know about psilocybin are the clinical results and what it does in the brain,” said Hecker. “These studies shed light on the fact that psilocybin has powerful impacts throughout the body.”

More research is needed

As these are the first studies that show the impact of psilocybin on aging, Hecker said there is still “much more to learn” about drug potential.

“What are the optimal dosage protocols for humans? What is the optimal age for the beginning of the treatment for optimal benefits?” Hecker questioned.

“Psilocybin seems to slow the ‘wear’ that accompanies aging.”

“Is there an age, beyond the point, when treatment does not provide efficiency?

Additional studies are needed to answer these questions and confirm whether the treatment affects the useful life, said Hecker.

Click here to get the News application

Gabe Charambides, founder of Odyssey, the first legal retirement of legal psilocybin of the United States, located in Oregon, said he considers these “convincing” findings.

“While most human psilocybin essays have focused on the results of mental health (depression, anxiety, PTSD, this work highlights physiological changes, including markers of cell aging,” he said in an interview with News Digital.

While Charambides withdrawal does not prove any biological change, he said that many guests report relief of physical ailments such as chronic pain and migraines.

“These self -reports suggest that the effects of the mind and the body that the study hints can also translate to humans,” he told News Digital.

Click here to register in our health newsletter

Psilocybin administration must differ “sharply” from mice to humans in terms of detection, preparation and safeguards, observed Charambides.

People who benefit most from psilocybin therapy include those who “feel trapped” after significant life events, such as childhood trauma, divorce, professional agitation or duel, or people who aim to improve their mental health, he added.

Potential risks

Ryan Moss, scientific director of Filament Health, a company for the development of natural psychedelic medications of the clinical stage in Canada, has emphasized the importance of administering psychedelics in a safe environment.

For more health articles, visit www.Newsnews.com/health

“Psychedelic experiences can sometimes present anxiety, hallucinations and paranoia,” Moss told News Digital. “Some patients who use traditional psychedelic have informed having experienced adverse cardiovascular events during clinical trials.”

To mitigate these risks, Moss recommended that clinical trial participants receive exhaustive preparation and monitoring of trained professionals during sessions.